| Title: |
Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. |
| Authors: |
Schoenfeld, Adam J; Lee, Sylvia M; Doger de Speville, Bernard; Gettinger, Scott N; Hafliger, Simon; Sukari, Ammar; Papa, Sophie; Rodriguez-Moreno, Juan Francisco; Graf Finckenstein, Friedrich; Fiaz, Rana; Catlett, Melissa; Chen, Guang; Qi, Rongsu; Masteller, Emma L; Gontcharova, Viktoria; He, Kai |
| Source: |
Schoenfeld, Adam J; Lee, Sylvia M; Doger de Speville, Bernard; Gettinger, Scott N; Hafliger, Simon; Sukari, Ammar; Papa, Sophie; Rodriguez-Moreno, Juan Francisco; Graf Finckenstein, Friedrich; Fiaz, Rana; Catlett, Melissa; Chen, Guang; Qi, Rongsu; Masteller, Emma L; Gontcharova, Viktoria; He, Kai (2024). Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer discovery, 14(8), pp. 1389-1402. American Association for Cancer Research 10.1158/2159-8290.CD-23-1334 |
| Publisher Information: |
American Association for Cancer Research |
| Publication Year: |
2024 |
| Collection: |
BORIS (Bern Open Repository and Information System, University of Bern) |
| Subject Terms: |
610 Medicine & health |
| Description: |
In this phase 2 multicenter study, we evaluated the efficacy and safety of lifileucel (LN-145), an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non-small cell lung cancer (mNSCLC) who had received prior immunotherapy and progressed on their most recent therapy. The median number of prior systemic therapies was 2 (range, 1-6). Lifileucel was successfully manufactured using tumor tissue from different anatomic sites, predominantly lung. The objective response rate was 21.4% (6/28). Responses occurred in tumors with profiles typically resistant to immunotherapy, such as PD-L1-negative, low tumor mutational burden, and STK11 mutation. Two responses were ongoing at the time of data cutoff, including one complete metabolic response in a PD-L1-negative tumor. Adverse events were generally as expected and manageable. Two patients died of treatment-emergent adverse events: cardiac failure and multiple organ failure. Lifileucel is a potential treatment option for patients with mNSCLC refractory to prior therapy. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://boris.unibe.ch/195558/ |
| Availability: |
https://boris.unibe.ch/195558/1/cd-23-1334.pdf; https://boris.unibe.ch/195558/ |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.A27FBE63 |
| Database: |
BASE |